Portage Accounts Payable from 2010 to 2024

PRTG Stock  USD 4.87  0.15  3.18%   
Portage Biotech's Accounts Payable is increasing over the last several years with very volatile swings. Accounts Payable is predicted to flatten to about 304.4 K. Accounts Payable is the amount Portage Biotech owes to suppliers or vendors for products or services received but not yet paid for. It represents Portage Biotech's short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2000-12-31
Previous Quarter
482 K
Current Value
1.5 M
Quarterly Volatility
1.3 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Portage Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Portage Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 51.3 K, Other Operating Expenses of 19.2 M or Total Operating Expenses of 19.1 M, as well as many indicators such as Price To Sales Ratio of 2 K, Dividend Yield of 0.0 or PTB Ratio of 53.14. Portage financial statements analysis is a perfect complement when working with Portage Biotech Valuation or Volatility modules.
  
Check out the analysis of Portage Biotech Correlation against competitors.
For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.

Latest Portage Biotech's Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Portage Biotech over the last few years. An accounting item on the balance sheet that represents Portage Biotech obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Portage Biotech are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Portage Biotech's Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Portage Biotech's overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Very volatile
   Accounts Payable   
       Timeline  

Portage Accounts Payable Regression Statistics

Arithmetic Mean291,703
Geometric Mean238,568
Coefficient Of Variation56.54
Mean Deviation133,036
Median299,740
Standard Deviation164,938
Sample Variance27.2B
Range579.4K
R-Value0
Mean Square Error29.3B
R-Squared0.00000242
Significance1.00
Slope57.38
Total Sum of Squares380.9B

Portage Accounts Payable History

2024304.4 K
2023482 K
2022274 K
2021188 K
2020113 K
2019343 K
2018388 K

About Portage Biotech Financial Statements

Portage Biotech stakeholders use historical fundamental indicators, such as Portage Biotech's Accounts Payable, to determine how well the company is positioned to perform in the future. Although Portage Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in Portage Biotech's assets and liabilities are reflected in the revenues and expenses on Portage Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Portage Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Accounts Payable482 K304.4 K

Currently Active Assets on Macroaxis

When determining whether Portage Biotech is a strong investment it is important to analyze Portage Biotech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Portage Biotech's future performance. For an informed investment choice regarding Portage Stock, refer to the following important reports:
Check out the analysis of Portage Biotech Correlation against competitors.
For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Portage Biotech. If investors know Portage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Portage Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
24.4
Return On Assets
(0.19)
Return On Equity
(1.91)
The market value of Portage Biotech is measured differently than its book value, which is the value of Portage that is recorded on the company's balance sheet. Investors also form their own opinion of Portage Biotech's value that differs from its market value or its book value, called intrinsic value, which is Portage Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Portage Biotech's market value can be influenced by many factors that don't directly affect Portage Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Portage Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Portage Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Portage Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.